2-(Arylamino)-6-(trifluoromethyl)nicotinic Acid Derivatives: New HIV-1 RT Dual Inhibitors Active on Viral Replication
Open accessThe DOI matches its Crossref record; 68 of the 70 references it cites were found in a registry or an index.
Abstract
The persistence of the AIDS epidemic, and the life-long treatment required, indicate the constant need of novel HIV-1 inhibitors. In this scenario the HIV-1 Reverse Transcriptase (RT)-associated ribonuclease H (RNase H) function is a promising drug target. Here we report a series of compounds, developed on the 2-amino-6-(trifluoromethyl)nicotinic acid scaffold, studied as promising RNase H dual inhibitors. Among the 44 tested compounds, 34 inhibited HIV-1 RT-associated RNase H function in the low micromolar range, and seven of them showed also to inhibit viral replication in cell-based assays with a selectivity index up to 10. The most promising compound, 21, inhibited RNase H function with an IC50 of 14 µM and HIV-1 replication in cell-based assays with a selectivity index greater than 10. Mode of action studies revealed that compound 21 is an allosteric dual-site compound inhibiting both HIV-1 RT functions, blocking the polymerase function also in presence of mutations carried by circulating variants resistant to non-nucleoside inhibitors, and the RNase H function interacting with conserved regions within the RNase H domain. Proving compound 21 as a promising lead for the design of new allosteric RNase H inhibitors active against viral replication with not significant cytotoxic effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Indeed, NNRTIs were found to modulate RNH activity upon recognition of the NNRTI binding site in the polymerase domain [101-103].”
From Retroviral RNase H: structure, mechanism, and inhibition (2021) · cites this paper as [103]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The end of AIDS: HIV infection as a chronic disease
Deeks, S. G., Lewin, S. R., & Havlir, D. V. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61809-7 · Cited by 2,063 · cited 1×
“While the highly-active antiretroviral therapy (HAART) allows patients who receive optimum treatment a life-expectation comparable to that of the uninfected population [2,3], the sub-optimal adherence and coverage of seropositive people, coupled with life-long treatment, still cause emergence of drug-resistant variant…”
BackgroundUPDATE ON DRUG RESISTANCE MUTATIONS IN HIV-1
&NA; (2001) · Infectious Diseases in Clinical Practice · doi:10.1097/00019048-200106000-00020 · Cited by 1,660
Wei, X., Decker, J. M., Liu, H., Zhang, Z., Arani, R. B., Kilby, J. M., Saag, M. S., Wu, X., Shaw, G. M., & Kappes, J. C. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.6.1896-1905.2002 · Cited by 1,569 · cited 1×
“Luciferase activity was measured as reported [67].”
Crystal structure of the ribonuclease H domain of HIV-1 reverse transcriptase
Davies, J. F., Hostomska, Z., Hostomsky, Z., Jordan, S. R., & Matthews, D. A. (1991) · Science · doi:10.1126/science.1707186 · Cited by 570 · cited 1×
“HIV-1 RT-associated RNase H is an enzymatic function present in all the members of the Ortervirales order [10] and it belongs to the nucleotidyltransferase family, characterized by a highly conserved Asp-Asp-Glu (DDE) motif, essential for coordination of two Mg2+ ions, and by a tertiary structure [11] conserved among…”
BackgroundPolypharmacology: drug discovery for the future
Reddy, A. S., & Zhang, S. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.12.74 · Cited by 479 · cited 1×
“Dual inhibitors are a new class of molecules that aim to increase the efficacy of the drug and raise the genetic barrier to overcome the selection of resistant strains by hitting two targets at the same time [44,51,52].”
BackgroundPolypharmacology – Foe or Friend?
Peters, J.-U. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400856t · Cited by 465 · cited 1×
“Dual inhibitors are a new class of molecules that aim to increase the efficacy of the drug and raise the genetic barrier to overcome the selection of resistant strains by hitting two targets at the same time [44,51,52].”
BackgroundGregson, J., Tang, M., Ndembi, N., Hamers, R. L., Rhee, S.-Y., Marconi, V. C., Diero, L., Brooks, K. A., Theys, K., Rinke de Wit, T., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00536-8 · Cited by 267
2019 update of the drug resistance mutations in HIV-1.
Wensing, A. M. J., Cálvez, V., Ceccherini‐Silberstein, F., Charpentier, C., Günthard, H. F., Paredes, R., Shafer, R. W., & Richman, D. D. (2019) · PubMed · Cited by 230
Tadokoro, T., & Kanaya, S. (2009) · The FEBS Journal · doi:10.1111/j.1742-4658.2009.06907.x · Cited by 202
Collective Motions in HIV-1 Reverse Transcriptase: Examination of Flexibility and Enzyme Function
Bahar, I., Erman, B., Jernigan, R. L., Atilgan, A. R., & Covell, D. G. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.2371 · Cited by 201 · cited 1×
“In the constant need to identify and develop new anti-HIV drugs, possibly active against circulating drug-resistant variants, this approach has been applied to RDDP/Integrase and RNase H/Integrase dual inhibitors [53–61], that target two different viral enzymes, and to RNase H/RDDP dual inhibitors, that target two dis…”
MethodSlide into Action: Dynamic Shuttling of HIV Reverse Transcriptase on Nucleic Acid Substrates
Liu, S., Abbondanzieri, E. A., Rausch, J. W., Grice, S. F. J. L., & Zhuang, X. (2008) · Science · doi:10.1126/science.1163108 · Cited by 162 · cited 2×
“In the constant need to identify and develop new anti-HIV drugs, possibly active against circulating drug-resistant variants, this approach has been applied to RDDP/Integrase and RNase H/Integrase dual inhibitors [53–61], that target two different viral enzymes, and to RNase H/RDDP dual inhibitors, that target two dis…”
BackgroundMethodRNases H: Structure and mechanism
Hyjek, M., Figiel, M., & Nowotny, M. (2019) · DNA Repair · doi:10.1016/j.dnarep.2019.102672 · Cited by 160
Himmel, D. M., Sarafianos, S. G., Dharmasena, S., Hossain, M. M., McCoy-Simandle, K., Ilina, T., Clark, A. D., Knight, J. L., Julias, J. G., Clark, P. K., et al. (2006) · ACS Chemical Biology · doi:10.1021/cb600303y · Cited by 140 · cited 2×
“Site-directed mutagenesis experiments showed that compound 21 binds independently to two different allosteric sites previously described: S first pocket (pocket 1), contiguous with the NNRTI binding pocket, was described for hydrazones [35], isatines [41,42] and pyrazoles [40].”
BackgroundHimmel, D. M., Maegley, K. A., Pauly, T. A., Bauman, J. D., Das, K., Dharia, C., Clark, A. D., Ryan, K., Hickey, M. J., Love, R. A., et al. (2009) · Structure · doi:10.1016/j.str.2009.09.016 · Cited by 140
Ortervirales: New Virus Order Unifying Five Families of Reverse-Transcribing Viruses
Krupovic, M., Blomberg, J., Coffin, J. M., Dasgupta, I., Fan, H., Geering, A. D., Gifford, R., Harrach, B., Hull, R., Johnson, W., et al. (2018) · Journal of Virology · doi:10.1128/jvi.00515-18 · Cited by 118
Esposito, F., Carli, I., Vecchio, C. D., Xu, L., Corona, A., Grandi, N., Piano, D., Maccioni, E., Distinto, S., Parolin, C., et al. (2016) · Phytomedicine · doi:10.1016/j.phymed.2016.08.001 · Cited by 97 · cited 1×
“activity profile against RDDP activity different from EFV on K103N and Y181C RTs, since these amino acid substitutions had a lower impact on its efficacy as compared to previously reported compounds [40,42,64].”
ResultSelf-citationRetroviral Integrase Structure and DNA Recombination Mechanism
Engelman, A., & Cherepanov, P. (2014) · Microbiology Spectrum · doi:10.1128/microbiolspec.mdna3-0024-2014 · Cited by 94
Toward an AIDS-Free Generation
Fauci, A. S., & Folkers, G. K. (2012) · JAMA · doi:10.1001/jama.2012.8142 · Cited by 86
Cuzzucoli Crucitti, G., Métifiot, M., Pescatori, L., Messore, A., Madia, V. N., Pupo, G., Saccoliti, F., Scipione, L., Tortorella, S., Esposito, F., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501799k · Cited by 81
Self-citationNarang, R., Narasimhan, B., Sharma, S., Sriram, D., Yogeeswari, P., Clercq, E. D., Pannecouque, C. C., & Balzarini, J. M. (2011) · Medicinal Chemistry Research · doi:10.1007/s00044-011-9664-7 · Cited by 80 · cited 2×
“In this case, the central core was represented by the 6-(trifluoromethyl)nicotinic acid, and, differently from the previous attempt to design nicotinate-based antimicrobial agents that had two aromatic functions [45,46], we decorated the core, making ester or amide of the nicotinic acid and introducing an arylamino mo…”
BackgroundDivita, G., Restle, T., Goody, R. S., Chermann, J. C., & Baillon, J. G. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)36800-x · Cited by 78 · cited 1×
“Differently, the first approaches to allosteric RNase H inhibition attempted to disrupt the enzyme stability by inhibiting the dimerization [30], and several efforts have been made to develop ligands able to bind at the interface between the heterodimer subunits [31–33], compromising RT heterodimer stability and flexi…”
BackgroundJudge, V., Narasimhan, B., Ahuja, M., Sriram, D., Yogeeswari, P., Clercq, E. D., Pannecouque, C. C., & Balzarini, J. M. (2012) · Medicinal Chemistry · doi:10.2174/157340613804488404 · Cited by 71
HIV-1 reverse transcriptase inhibition by a dipyridodiazepinone derivative: BI-RG-587
Tramontano, E., & Cheng, Y. (1992) · Biochemical Pharmacology · doi:10.1016/0006-2952(92)90515-k · Cited by 69 · cited 1×
“The allosteric inhibition of the polymerase function of RT was achieved in the 1990s [27] with non-nucleoside inhibitors (NNRTI) that are still in the first-line therapy [28], although displaying a fairly low genetic barrier to selection of resistant variants, among which K103N, Y181C, and Y188L are the most common [2…”
MethodSelf-citationIsatin thiazoline hybrids as dual inhibitors of HIV-1 reverse transcriptase
Meleddu, R., Distinto, S., Corona, A., Tramontano, E., Bianco, G., Melis, C., Cottiglia, F., & Maccioni, E. (2016) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2016.1238366 · Cited by 69 · cited 3×
“Site-directed mutagenesis experiments showed that compound 21 binds independently to two different allosteric sites previously described: S first pocket (pocket 1), contiguous with the NNRTI binding pocket, was described for hydrazones [35], isatines [41,42] and pyrazoles [40].”
BackgroundSelf-citationEsposito, F., & Tramontano, E. (2014) · Antiviral Chemistry and Chemotherapy · doi:10.3851/imp2690 · Cited by 68
Self-citationCorona, A., Di Leva, F. S., Thierry, S., Pescatori, L., Cuzzucoli Crucitti, G., Subra, F., Delelis, O., Esposito, F., Rigogliuso, G., Costi, R., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03605-14 · Cited by 68
Self-citationCamarasa, M.-J., Velázquez, S., San-Félix, A., Pérez-Pérez, M.-J., & Gago, F. (2006) · Antiviral Research · doi:10.1016/j.antiviral.2006.05.021 · Cited by 66
Distinto, S., Esposito, F., Kirchmair, J., Cardia, M. C., Gaspari, M., Maccioni, E., Alcaro, S., Markt, P., Wolber, G., Zinzula, L., et al. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.01.056 · Cited by 64
Self-citationThe Role of HIV-1 Drug-Resistant Minority Variants in Treatment Failure
Stella-Ascariz, N., Arribas, J. R., Paredes, R., & Li, J. Z. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix430 · Cited by 62
Meleddu, R., Distinto, S., Corona, A., Bianco, G., Cannas, V., Esposito, F., Artese, A., Alcaro, S., Mátyus, P., Bogdán, D., et al. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.02.032 · Cited by 58
Self-citationCorona, A., Meleddu, R., Esposito, F., Distinto, S., Bianco, G., Masaoka, T., Maccioni, E., Menéndez-Arias, L., Alcaro, S., Le Grice, S. F. J., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0147225 · Cited by 56 · cited 10×
“Heterodimeric RT was expressed essentially as described [42].”
BackgroundMethodResultSelf-citationCosti, R., Métifiot, M., Chung, S., Cuzzucoli Crucitti, G., Maddali, K., Pescatori, L., Messore, A., Madia, V. N., Pupo, G., Scipione, L., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5001503 · Cited by 55
Self-citationActive site and allosteric inhibitors of the ribonuclease H activity of HIV reverse transcriptase
Corona, A., Masaoka, T., Tocco, G., Tramontano, E., & Le Grice, S. F. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.178 · Cited by 54
Self-citationPescatori, L., Métifiot, M., Chung, S., Masoaka, T., Crucitti, G. C., Messore, A., Pupo, G., Madia, V. N., Saccoliti, F., Scipione, L., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00159 · Cited by 53
Ribonuclease H, an unexploited target for antiviral intervention against HIV and hepatitis B virus
Tramontano, E., Corona, A., & Menéndez-Arias, L. (2019) · Antiviral Research · doi:10.1016/j.antiviral.2019.104613 · Cited by 53
Self-citationde Castro, S., & Camarasa, M. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.03.007 · Cited by 52
Judge, V., Narasimhan, B., Ahuja, M., Sriram, D., Yogeeswari, P., Clercq, E. D., Pannecouque, C. C., & Balzarini, J. M. (2011) · Medicinal Chemistry Research · doi:10.1007/s00044-011-9705-2 · Cited by 51 · cited 2×
“In this case, the central core was represented by the 6-(trifluoromethyl)nicotinic acid, and, differently from the previous attempt to design nicotinate-based antimicrobial agents that had two aromatic functions [45,46], we decorated the core, making ester or amide of the nicotinic acid and introducing an arylamino mo…”
BackgroundCurrent and future priorities for the development of optimal HIV drugs
Vitoria, M., Rangaraj, A., Ford, N., & Doherty, M. (2019) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000527 · Cited by 50 · cited 1×
“The allosteric inhibition of the polymerase function of RT was achieved in the 1990s [27] with non-nucleoside inhibitors (NNRTI) that are still in the first-line therapy [28], although displaying a fairly low genetic barrier to selection of resistant variants, among which K103N, Y181C, and Y188L are the most common [2…”
MethodWang, X., Gao, P., Menendez-Arias, L., Liu, X., & Zhan, P. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867324666170113110839 · Cited by 49
Chung, S., Wendeler, M., Rausch, J. W., Beilhartz, G., Gotte, M., O'Keefe, B. R., Bermingham, A., Beutler, J. A., Liu, S., Zhuang, X., et al. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00434-10 · Cited by 47 · cited 1×
“Differently, the first approaches to allosteric RNase H inhibition attempted to disrupt the enzyme stability by inhibiting the dimerization [30], and several efforts have been made to develop ligands able to bind at the interface between the heterodimer subunits [31–33], compromising RT heterodimer stability and flexi…”
BackgroundInteraction of HIV‐1 Reverse Transcriptase Ribonuclease H with an Acylhydrazone Inhibitor
Gong, Q., Menon, L., Ilina, T., Miller, L. G., Ahn, J., Parniak, M. A., & Ishima, R. (2011) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2010.01052.x · Cited by 43 · cited 3×
“Besides, both compounds were tested also on RTs mutated in two amino acid residues within the RNase H domain, Q475A and A502F, part of conserved regions of RNase H domain [50], that have been shown to be involved in the binding of RNase H inhibitors into a pocket close to the RNase H catalytic site but acting as allos…”
BackgroundMolecular Aspects of the RT/drug Interactions. Perspective of Dual Inhibitors
Distinto, S., Maccioni, E., Meleddu, R., Corona, A., Alcaro, S., & Tramontano, E. (2013) · Current Pharmaceutical Design · doi:10.2174/1381612811319100009 · Cited by 42
Self-citationCorona, A., Onnis, V., Deplano, A., Bianco, G., Demurtas, M., Distinto, S., Cheng, Y., Alcaro, S., Esposito, F., & Tramontano, E. (2017) · Pathogens and Disease · doi:10.1093/femspd/ftx078 · Cited by 40
Self-citationDeveloping and Evaluating Inhibitors against the RNase H Active Site of HIV-1 Reverse Transcriptase
Boyer, P. L., Smith, S. J., Zhao, X. Z., Das, K., Gruber, K., Arnold, E., Burke, T. R., & Hughes, S. H. (2018) · Journal of Virology · doi:10.1128/jvi.02203-17 · Cited by 38 · cited 1×
“The RNase H active-site inhibitors take advantage of the driving force represented by their chelating moiety to stably interact with the catalytic domain [21,22]; however, their development is often hampered by off-target toxicity and competition with nucleic acid substrates [23,24], and by the difficulties to establi…”
BackgroundWang, L., Tang, J., Huber, A. D., Casey, M. C., Kirby, K. A., Wilson, D. J., Kankanala, J., Xie, J., Parniak, M. A., Sarafianos, S. G., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.07.039 · Cited by 36 · cited 1×
“The RNase H active-site inhibitors take advantage of the driving force represented by their chelating moiety to stably interact with the catalytic domain [21,22]; however, their development is often hampered by off-target toxicity and competition with nucleic acid substrates [23,24], and by the difficulties to establi…”
BackgroundChristen, M. T., Menon, L., Myshakina, N. S., Ahn, J., Parniak, M. A., & Ishima, R. (2012) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12010 · Cited by 35 · cited 4×
“In the constant need to identify and develop new anti-HIV drugs, possibly active against circulating drug-resistant variants, this approach has been applied to RDDP/Integrase and RNase H/Integrase dual inhibitors [53–61], that target two different viral enzymes, and to RNase H/RDDP dual inhibitors, that target two dis…”
BackgroundMethodInfluentialNatural Product Kuwanon‐L Inhibits HIV‐1 Replication through Multiple Target Binding
Martini, R., Esposito, F., Corona, A., Ferrarese, R., Ceresola, E. R., Visconti, L. M., Tintori, C., Barbieri, A., Calcaterra, A., Iovine, V., et al. (2016) · ChemBioChem · doi:10.1002/cbic.201600592 · Cited by 34
Self-citationSun, L., Gao, P., Dong, G., Zhang, X., Cheng, X., Ding, X., Wang, X., Daelemans, D., Clercq, E. D., Pannecouque, C. C., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.06.036 · Cited by 33
Costa, G., Rocca, R., Corona, A., Grandi, N., Moraca, F., Romeo, I., Talarico, C., Gagliardi, M. G., Ambrosio, F. A., Ortuso, F., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.10.029 · Cited by 30 · cited 1×
“The HIV-1 RT-associated RDDP activity was measured as described [66].”
MethodSelf-citationCorona, A., Schneider, A., Schweimer, K., ROSCH, P. J., Wöhrl, B. M., & Tramontano, E. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00056-14 · Cited by 27
Self-citationMeleddu, R., Cannas, V., Distinto, S., Sarais, G., Vecchio, C. D., Esposito, F., Bianco, G., Corona, A., Cottiglia, F., Alcaro, S., et al. (2014) · ChemMedChem · doi:10.1002/cmdc.201402015 · Cited by 26
Self-citationSchneider, A., Corona, A., Spöring, I., Jordan, M. A., Buchholz, B. M., Maccioni, E., Santo, R. D., Bodem, J., Tramontano, E., & Wöhrl, B. M. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw060 · Cited by 26
Self-citationCocco, M. T., Congiu, C., Onnis, V., Morelli, M., Felipo, V., & Cauli, O. (2004) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2004.05.025 · Cited by 26 · cited 4×
“We have previously reported an easy and convenient method for the synthesis of 2‐arylamino‐6‐trifluoromethyl‐3‐pyridinecarboxylic acids [47].”
MethodSelf-citationAlcaro, S., Artese, A., Ceccherini‐Silberstein, F., Chiarella, V., Dimonte, S., Ortuso, F., & Perno, C. F. (2009) · Current Medicinal Chemistry · doi:10.2174/092986710790192695 · Cited by 25
Esposito, F., Sechi, M., Pala, N., Sanna, A., Koneru, P. C., Kvaratskhelia, M., Naesens, L. M. J., Corona, A., Grandi, N., Santo, R. D., et al. (2019) · Antiviral Research · doi:10.1016/j.antiviral.2019.104671 · Cited by 24
Self-citationOnnis, V., Cocco, M. T., Lilliu, V., & Congiu, C. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.11.069 · Cited by 23 · cited 6×
“Amide derivatives 25‐52 (Table 1) were obtained in 39%–96% yields by the reaction of acid 10 with the appropriate amine by EDCI method[48].”
MethodSelf-citationAntiretroviral activity of metal-chelating HIV-1 integrase inhibitors
Carcelli, M., Rogolino, D., Sechi, M., Rispoli, G., Fisicaro, E., Compari, C., Grandi, N., Corona, A., Tramontano, E., Pannecouque, C. C., et al. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.06.055 · Cited by 23
Self-citationInhibition of HIV‐1 Reverse Transcriptase Dimerization by Small Molecules
Tintori, C., Corona, A., Esposito, F., Brai, A., Grandi, N., Ceresola, E. R., Clementi, M., Canducci, F., Tramontano, E., & Botta, M. (2016) · ChemBioChem · doi:10.1002/cbic.201500668 · Cited by 22
Self-citationPyridopyrimidinone inhibitors of HIV-1 RNase H
Velthuisen, E. J., Johns, B. A., Gerondelis, P., Chen, Y., Li, M., Mou, K., Zhang, W., Seal, J. W., Hightower, K. E., Miranda, S. R., et al. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.06.061 · Cited by 20
Massari, S., Corona, A., Distinto, S., Desantis, J., Caredda, A., Sabatini, S., Manfroni, G., Felicetti, T., Cecchetti, V., Pannecouque, C., et al. (2019) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2018.1523901 · Cited by 19
Self-citationCorona, A., Esposito, F., & Tramontano, E. (2014) · Future Virology · doi:10.2217/fvl.14.24 · Cited by 18 · cited 1×
“None of them has reached the clinical trial so far, enlightening the level of difficulty represented by the target [20].”
BackgroundSelf-citationPoongavanam, V., Corona, A., Steinmann, C., Scipione, L., Grandi, N., Pandolfi, F., Santo, R. D., Costi, R., Esposito, F., Tramontano, E., et al. (2018) · MedChemComm · doi:10.1039/c7md00600d · Cited by 18 · cited 1×
“The RNase H active-site inhibitors take advantage of the driving force represented by their chelating moiety to stably interact with the catalytic domain [21,22]; however, their development is often hampered by off-target toxicity and competition with nucleic acid substrates [23,24], and by the difficulties to establi…”
BackgroundSelf-citationGao, P., Cheng, X., Sun, L., Song, S. L., Álvarez, M., Luczkowiak, J., Pannecouque, C. C., Clercq, E. D., Menéndez‐Arias, L., Zhan, P., et al. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.07.011 · Cited by 17
Retroviral reverse transcription
Menéndez‐Arias, L., & Berkhout, B. (2008) · Virus Research · doi:10.1016/j.virusres.2008.01.009 · Cited by 15 · cited 1×
“RT is a heterodimeric (p66/p51) multifunctional enzyme that acts at the early stage of viral infection by converting the viral single-stranded RNA genome into a double-stranded DNA, with the concerted and dynamic interplay of its enzymatic functions RNA- and DNA-dependent DNA polymerase (RDDP and DDDP, respectively),…”
BackgroundPala, N., Esposito, F., Rogolino, D., Carcelli, M., Sanna, V., Palomba, M., Naesens, L. M. J., Corona, A., Grandi, N., Tramontano, E., et al. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17081371 · Cited by 14 · cited 1×
“The RT-associated RNase H activity of wt and mutated HIV RTs was measured as described [65], in 100 μL reaction volume containing 50 mM Tris HCl pH 7.”
MethodSelf-citationSánchez‐Murcia, P. A., de Castro, S., Garcı́a-Aparicio, C., Jiménez, M. A., Corona, A., Tramontano, E., Sluis‐Cremer, N., Menéndez‐Arias, L., Velázquez, S., Gago, F., et al. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00623 · Cited by 13
Self-citationDeterminants of Active-Site Inhibitor Interaction with HIV-1 RNase H
Xi, Z., Wang, Z., Sarafianos, S. G., Myshakina, N. S., & Ishima, R. (2019) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.9b00300 · Cited by 13 · cited 1×
“The RNase H active-site inhibitors take advantage of the driving force represented by their chelating moiety to stably interact with the catalytic domain [21,22]; however, their development is often hampered by off-target toxicity and competition with nucleic acid substrates [23,24], and by the difficulties to establi…”
BackgroundFollowing the path: Increasing trends of HIV-1 drug resistance in China
Gupta, S., & Neogi, U. (2020) · EClinicalMedicine · doi:10.1016/j.eclinm.2019.100251 · Cited by 7
Cited by
Du, S., Hu, X., Menéndez‐Arias, L., Zhan, P., & Liu, X. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2024.101053 · Cited by 61
Zhang, K., Zhang, Y., Li, M., Pannecouque, C. C., Clercq, E. D., Wang, S., & Chen, F. (2024) · Medicinal Research Reviews · doi:10.1002/med.22080 · Cited by 35
Recent Trends in Enzyme Inhibition and Activation in Drug Design
Geronikaki, A. A. (2020) · Molecules · doi:10.3390/molecules26010017 · Cited by 25
“[3] presented the synthesis and testing of forty-four compounds based on 2-amino-6-(trifluoromethyl)nicotinic acid scaffold as promising RNase H dual inhibitors.”
MethodCurrent medicinal chemistry strategies in the discovery of novel HIV-1 ribonuclease H inhibitors
Zhang, L., Wei, F., Zhang, J., Liu, C., López‐Carrobles, N., Liu, X., Menéndez‐Arias, L., & Zhan, P. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114760 · Cited by 21
Kang, J.-X., Zhao, G.-K., Yang, X., Huang, M.-X., Hui, W., Zeng, R., & Ouyang, Q. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115196 · Cited by 19
Metadata
- Authors
- Corona, A., Onnis, V., Del Vecchio, C., Esposito, F., Cheng, Y.-C., & Tramontano, E.
- Affiliations
- University of Cagliari (IT)
- Department of Molecular Medicine, University of Padova, 35121 Padova, Italy
- Yale University (US)
- University of Padua (IT)
- Corresponding author
- Tramontano, Enzo
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2020-03-15
- Volume
- 25
- Issue
- 6
- Pages
- 1338
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC7144554
- OpenAlex
- W3012081745
- Semantic Scholar
- 1d399d23a40a38222ce6a1e4c0b8836319f84d91
- Cited by
- 19
- References
- 70
- Citations by year
- 2026: 3 · 2025: 1 · 2024: 6 · 2023: 3 · 2022: 1 · 2021: 3 · 2020: 2
- FWCI
- 0.29
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- UNICA IRIS Institutional Research Information System (University of Cagliari) (submittedVersion, cc-by)
- Funders
- Regione Autonoma della Sardegna (F76C18000800002)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- HIV-1 reverse transcriptase, RNase H, dual inhibitors, allosteric inhibitors, HIV-1 replication inhibition, antiviral drug design, non-nucleoside reverse transcriptase inhibitors, drug selectivity index, viral replication
- MeSH terms
- Allosteric Regulation, Humans, Virus Replication, HIV-1, Ribonuclease H, Reverse Transcriptase Inhibitors, Anti-HIV Agents, Cell Line, Tumor, HIV Reverse Transcriptase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.